Urogen Pharma Stock Analysis
| URGN Stock | USD 11.01 0.27 2.51% |
UroGen Pharma is fairly valued with Real Value of 11.21 and Target Price of 39.93. The main objective of UroGen Pharma stock analysis is to determine its intrinsic value, which is an estimate of what UroGen Pharma is worth, separate from its market price. There are two main types of UroGen Pharma's stock analysis: fundamental analysis and technical analysis.
The UroGen Pharma stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. UroGen Pharma is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day. UroGen Stock trading window is adjusted to America/New York timezone.
UroGen |
UroGen Stock Analysis Notes
About 92.0% of the company outstanding shares are owned by institutional investors. The company has Price/Earnings (P/E) ratio of 239.57. UroGen Pharma recorded a loss per share of 3.02. The entity had not issued any dividends in recent years. UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey. Urogen Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 201 people. For more information please call Elizabeth Barrett at 646 768 9780 or visit https://www.urogen.com.UroGen Pharma Investment Alerts
| UroGen Pharma generated a negative expected return over the last 90 days | |
| UroGen Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 82.71 M. Net Loss for the year was (102.24 M) with profit before overhead, payroll, taxes, and interest of 80.67 M. | |
| UroGen Pharma currently holds about 111.74 M in cash with (76.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.91. | |
| Over 92.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Degnan Chris of 13450 shares of UroGen Pharma subject to Rule 16b-3 |
UroGen Pharma Upcoming and Recent Events
Earnings reports are used by UroGen Pharma to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
UroGen Largest EPS Surprises
Earnings surprises can significantly impact UroGen Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-11-14 | 2017-09-30 | -0.05 | -0.02 | 0.03 | 60 | ||
2024-05-13 | 2024-03-31 | -0.87 | -0.97 | -0.1 | 11 | ||
2018-03-15 | 2017-12-31 | -0.62 | -0.74 | -0.12 | 19 |
UroGen Pharma Environmental, Social, and Governance (ESG) Scores
UroGen Pharma's ESG score is a quantitative measure that evaluates UroGen Pharma's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of UroGen Pharma's operations that may have significant financial implications and affect UroGen Pharma's stock price as well as guide investors towards more socially responsible investments.
UroGen Market Capitalization
The company currently falls under 'Small-Cap' category with a current market capitalization of 478.96 M.UroGen Profitablity
The company has Profit Margin (PM) of (1.29) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.7) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.7.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.52) | (0.54) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.52) | (0.54) | |
| Return On Equity | 1.80 | 1.89 |
Management Efficiency
UroGen Pharma has return on total asset (ROA) of (0.2112) % which means that it has lost $0.2112 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (14.8126) %, meaning that it created substantial loss on money invested by shareholders. UroGen Pharma's management efficiency ratios could be used to measure how well UroGen Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 31st of January 2025, Return On Equity is likely to grow to 1.89, while Return On Tangible Assets are likely to drop (0.54). At this time, UroGen Pharma's Total Assets are very stable compared to the past year. As of the 31st of January 2025, Other Current Assets is likely to grow to about 13.4 M, though Net Tangible Assets are likely to grow to (97.6 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.60) | (2.47) | |
| Tangible Book Value Per Share | (2.60) | (2.47) | |
| Enterprise Value Over EBITDA | (7.89) | (7.49) | |
| Price Book Value Ratio | (7.63) | (7.25) | |
| Enterprise Value Multiple | (7.89) | (7.49) | |
| Price Fair Value | (7.63) | (7.25) | |
| Enterprise Value | 221.4 M | 197.9 M |
At UroGen Pharma, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Technical Drivers
As of the 31st of January, UroGen Pharma has the Variance of 6.86, coefficient of variation of (2,323), and Risk Adjusted Performance of (0.03). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of UroGen Pharma, as well as the relationship between them.UroGen Pharma Price Movement Analysis
The output start index for this execution was thirty-five with a total number of output elements of twenty-six. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. UroGen Pharma middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for UroGen Pharma. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
UroGen Pharma Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific UroGen Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on UroGen Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases UroGen Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
UroGen Pharma Outstanding Bonds
UroGen Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. UroGen Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most UroGen bonds can be classified according to their maturity, which is the date when UroGen Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View |
UroGen Pharma Predictive Daily Indicators
UroGen Pharma intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of UroGen Pharma stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
UroGen Pharma Corporate Filings
8K | 14th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 18th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 8th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 24th of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
UroGen Pharma Forecast Models
UroGen Pharma's time-series forecasting models are one of many UroGen Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary UroGen Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About UroGen Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how UroGen Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling UroGen shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as UroGen Pharma. By using and applying UroGen Stock analysis, traders can create a robust methodology for identifying UroGen entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (1.07) | (1.12) | |
| Operating Profit Margin | (0.71) | (0.75) | |
| Net Loss | (1.11) | (1.17) | |
| Gross Profit Margin | 0.80 | 0.56 |
Current UroGen Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. UroGen analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. UroGen analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 39.93 | Strong Buy | 6 | Odds |
Most UroGen analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand UroGen stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of UroGen Pharma, talking to its executives and customers, or listening to UroGen conference calls.
UroGen Stock Analysis Indicators
UroGen Pharma stock analysis indicators help investors evaluate how UroGen Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading UroGen Pharma shares will generate the highest return on investment. By understating and applying UroGen Pharma stock analysis, traders can identify UroGen Pharma position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 56.2 M | |
| Long Term Debt | 98.6 M | |
| Common Stock Shares Outstanding | 28.8 M | |
| Total Stockholder Equity | -65.2 M | |
| Tax Provision | 755 K | |
| Property Plant And Equipment Net | 2.4 M | |
| Cash And Short Term Investments | 137 M | |
| Cash | 95 M | |
| Accounts Payable | 6.5 M | |
| Net Debt | 4.4 M | |
| 50 Day M A | 11.1966 | |
| Total Current Liabilities | 31.2 M | |
| Other Operating Expenses | 148.2 M | |
| Non Current Assets Total | 9.1 M | |
| Non Currrent Assets Other | 2.3 M | |
| Stock Based Compensation | 9.3 M |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share | Quarterly Revenue Growth 0.209 | Return On Assets | Return On Equity |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.